Article
SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association - 1 Nov 2018
Sugase Takahito, Takahashi Tsuyoshi, Serada Satoshi, Fujimoto Minoru, Ohkawara Tomoharu, Hiramatsu Kosuke, Nishida Toshirou, Hirota Seiichi, Saito Yurina, Tanaka Koji, Miyazaki Yasuhiro, Makino Tomoki, Kurokawa Yukinori, Yamasaki Makoto, Nakajima Kiyokazu, Hanasaki Kazuhiro, Kishimoto Tadamitsu, Mori Masaki, Doki Yuichiro, Naka Tetsuji
Abstract excerpt
BACKGROUND: Most of the gastrointestinal stromal tumors (GIST) have mutations in the KIT gene, encoding a receptor tyrosine kinase. Imatinib, a receptor tyrosine kinase inhibitor, is the first-line therapy for unresectable and metastatic GISTs. Despite the revolutionary effects of imatinib, some patients are primarily resistant to imatinib and many become resistant because of acquisition of secondary mutations in...
Topics
Join the communities discussing this publication.